循環器ジャーナル65巻3号

2017年07月発行

特集 不整脈診療—ずっと疑問・まだ疑問 Ⅱ．抗凝固療法を考える

DOACはどれも同じか

著者： 小谷英太郎¹

所属機関： ¹日本医科大学多摩永山病院内科・循環器内科

ページ範囲：P.463 - P.472

Point
・DOACとワルファリンは，目的は同じだが作用機序に大きな違いがある．
・トロンビン阻害薬と第Ⅹa因子阻害薬は，臨床的には大きな差はないが，ダビガトランには中和薬がある．
・第Ⅹa因子阻害薬間の有効性・安全性に大きな差はない．

参考文献

1) 循環器病の診断と治療に関するガイドライン（2012年度合同研究班報告）：心房細動治療（薬物）ガイドライン（2013年改訂版）．日本循環器学会，東京，2013　http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf

2) Connolly SJ, Ezekowitz MD, Yusuf S, et al:Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151, 2009

3) Connolly SJ, Ezekowitz MD, Yusuf S, et al:Newly identified events in the RE-LY trial. N Engl J Med 363:1875-1876, 2010

4) Patel MR, Mahaffey KW, Garg J, et al:Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891, 2011

5) Hori M, Matsumoto M, Tanahashi N, et al:Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J 76:2104-2111, 2012

6) Granger CB, Alexander JH, McMurray JJ, et al:Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992, 2011

7) Giugliano RP, Ruff CT, Braunwald E, et al:Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093-2104, 2013

8) Sato H, Ishikawa K, Kitabatake A, et al:Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation:Japan Atrial Fibrillation Stroke Trial. Stroke 37:447-451, 2006

9) Kirchhof P, Benussi S, Kotecha D, et al:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893-2962, 2016

10) January CT, Wann LS, Alpert JS, et al:2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1-e76, 2014

11) Gibson CM, Mehran R, Bode C, et al:Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423-2434, 2016

12) Connolly SJ, Eikelboom J, Joyner C, et al:Apixaban in patients with atrial fibrillation. N Engl J Med 364:806-817, 2011

13) Weinz C, Schwarz T, Kubitza D, et al:Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37:1056-1064, 2009

14) Raghavan N, Frost CE, Yu Z, et al:Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74-81, 2009

15) Camm AJ, Bounameaux H:Edoxaban:a new oral direct factor Xa inhibitor. Drugs 71:1503-1526, 2011

16) Eriksson BI, Quinlan DJ, Eikelboom JW:Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 62:41-57, 2011

17) Harder S, Graff J:Novel oral anticoagulants:clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 69:1617-1633，2013

18) 青﨑正彦，岩出和徳，越前宏俊：Warfarin適正使用情報　第3版．エーザイ株式会社，東京，2006

19) Hagii J, Tomita H, Metoki N, et al:Characteristics of intracerebral hemorrhage during rivaroxaban treatment:comparison with those during warfarin. Stroke 45:2805-2807, 2014

20) Yasaka M:Current strategies of anticoagulation therapy for patients with non-valvular atrial fibrillation. J Arrhythm 28:324-329, 2012

21) Saito S, Tomita H, Kimura Y, et al:Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient. J Stroke Cerebrovasc Dis 23:1747-1749, 2014

22) Eikelboom JW, Connolly SJ, Brueckmann M, et al:Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206-1214, 2013

23) Azoulay L, Dell' Aniello S, Simon TA, et al:Initiation of warfarin in patients with atrial fibrillation:early effects on ischaemic strokes. Eur Heart J 35:1881-1887, 2014

24) Inoue H, Uchiyama S, Atarashi H, et al:Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation:Preliminary report of the J-dabigatran surveillance. J Arrhythm 32:145-150, 2016

25) Macle L, Cairns J, Leblanc K, et al:2016 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 32:1170-1185, 2016

26) Ruff CT, Giugliano RP, Braunwald E, et al:Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials. Lancet 383:955-962, 2014

27) Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T:Rivaroxaban versus warfarin and dabigatran in atrial fibrillation:comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 25:1236-1244, 2016

28) Graham DJ, Reichman ME, Wernecke M, et al:Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 176:1662-1671, 2016

29) Okumura K, Hori M, Tanahashi N, et al:Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. Clin Cardiol 40:126-131, 2017